Company description

AVPT, or Avail Therapeutics, is a publicly traded biopharmaceutical company that specializes in developing innovative treatments for rare genetic diseases. The company was founded in 2017 and is headquartered in New York City. AVPT is committed to utilizing cutting-edge technology and collaborating with leading research institutions to bring life-changing therapies to patients suffering from rare genetic disorders. The company's extensive pipeline includes treatments for rare diseases such as Gaucher disease and Parkinson's disease. AVPT also has a strong focus on patient advocacy and works closely with patient communities to understand their needs and develop personalized treatments. With a dedicated team of experienced scientists and industry experts, AVPT is well-positioned to make a significant impact in the field of rare disease treatment. Their commitment to innovation, patient-centric approach, and strong pipeline make AVPT a promising company to watch in the biopharmaceutical industry.